Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer

NCT02259582 is registered in ClinicalTrials.gov with OncoMed Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02259582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02259582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
April 7, 2017
Enrollment
82 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

nonsquamous nonsmall cell neoplasm of lung